Black Rock Inc. Arcus Biosciences, Inc. Call Options Transaction History
Black Rock Inc.
- $4.35 Trillion
- Q2 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding RCUS
# of Institutions
211Shares Held
67MCall Options Held
3.18MPut Options Held
167K-
Vanguard Group Inc Valley Forge, PA6.56MShares$132 Million0.0% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct5.97MShares$120 Million0.11% of portfolio
-
Woodline Partners LP San Francisco, CA4MShares$80.8 Million0.19% of portfolio
-
Suvretta Capital Management, LLC New York, NY3.69MShares$74.5 Million1.03% of portfolio
-
State Street Corp Boston, MA3.63MShares$73.3 Million0.0% of portfolio
About Arcus Biosciences, Inc.
- Ticker RCUS
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 72,160,000
- Market Cap $1.46B
- Description
- Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for ...